Literature DB >> 16111796

Aberrant folate status in schizophrenic patients: what is the evidence?

Jan-Willem Muntjewerff1, Henk J Blom.   

Abstract

A vast amount of case reports, open studies and, to a lesser extent, case-control studies have been published on the topic of psychopathology and folate deficiency. These studies reported a high incidence of serum folate deficiency in patients with various psychiatric disorders. Folate deficiency seems to be a particular consistent finding in depressive patients. The evidence for an association between aberrant folate status and schizophrenia seems less convincing. The lack of stringent methodology such as inclusion of age- and sex-matched controls was thought to be the main reason for the inconclusive results. The purpose of this article is to review the published case-control studies that provide data on folate levels in the population of patients with schizophrenia. Data extracted from these studies comprised methodological design, clinical characteristics and folate measurements. We found that none of the 7 case-control studies included in this review (in total 325 cases and 560 control subjects) explicitly reported on all critical factors in the assessment of folate. In addition, only three studies found lower plasma folate levels more frequently in patients with schizophrenia compared to controls. Further research on this topic is required to clarify the relationship between folate status and schizophrenia and should avoid the methodological pitfalls mentioned in this review. In addition, research should also focus on polymorphisms of genes related to folate metabolism.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16111796     DOI: 10.1016/j.pnpbp.2005.06.024

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  5 in total

Review 1.  Fatty acid and vitamin interventions in adults with schizophrenia: a systematic review of the current evidence.

Authors:  Siok Ching Chia; Jeyakumar Henry; Yee Ming Mok; William G Honer; Kang Sim
Journal:  J Neural Transm (Vienna)       Date:  2015-09-09       Impact factor: 3.575

Review 2.  Diet and the epigenetic (re)programming of phenotypic differences in behavior.

Authors:  Patrick O McGowan; Michael J Meaney; Moshe Szyf
Journal:  Brain Res       Date:  2008-07-29       Impact factor: 3.252

3.  Metabolic syndrome and insulin resistance in schizophrenia patients receiving antipsychotics genotyped for the methylenetetrahydrofolate reductase (MTHFR) 677C/T and 1298A/C variants.

Authors:  Vicki L Ellingrod; Del D Miller; Stephan F Taylor; Jessica Moline; Timothy Holman; Jane Kerr
Journal:  Schizophr Res       Date:  2007-10-31       Impact factor: 4.939

4.  Folic acid supplementation before and during pregnancy in the Newborn Epigenetics STudy (NEST).

Authors:  Cathrine Hoyo; Amy P Murtha; Joellen M Schildkraut; Michele R Forman; Brian Calingaert; Wendy Demark-Wahnefried; Joanne Kurtzberg; Randy L Jirtle; Susan K Murphy
Journal:  BMC Public Health       Date:  2011-01-21       Impact factor: 3.295

5.  MTHFR gene polymorphism and age of onset of schizophrenia and bipolar disorder.

Authors:  Mohamed A El-Hadidy; Hanaa M Abdeen; Sherin M Abd El-Aziz; Mohammad Al-Harrass
Journal:  Biomed Res Int       Date:  2014-07-03       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.